Sequences of the primers used for Sanger sequencing. Table S2. Comprehensive list of variants from targed re-sequencing of blood, ovarian cancer, endometrial cancer and lung metastasis. (xlsx
Statistics of sequencing results. Sequence coverage by Comprehensive Cancer Panel (Thermo Scientific...
Pathogenic mutations in BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) genes (n = 96) detected in 398 p...
Table S1. Sequencing parameters for 3 samples with the highest and 3 samples with the lowest sequenc...
Areas used for DNA extraction in the endometrial (A, B) and ovarian (C, D) carcinoma and the lung me...
Clinicopathological data for MOTs. Table S2. Summary of whole exome sequencing statistics. Table S3....
Figure S1. Result of sanger sequencing. (A) Eleven mutations which were sanger sequenced. (B) - (H) ...
Sample information of 587 ovarian patients and normal tissue samples with Copy number variation and ...
Table S1. The primer of Sanger sequence for specific genes mutation in FDOV1. (DOCX 15 kb
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Clinical description of cancer patients. Table S2. Statistics of whole-genome sequencing results. Ta...
Table S1. 48 genes included in the TruSeq Amplicon Cancer Panel (TSACP, Illumina), which includes 21...
Figure S2. Distribution of genes with novel mutations based on individual patients. (A) Distribution...
Statistics of sequencing results. Sequence coverage by Comprehensive Cancer Panel (Thermo Scientific...
Pathogenic mutations in BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) genes (n = 96) detected in 398 p...
Table S1. Sequencing parameters for 3 samples with the highest and 3 samples with the lowest sequenc...
Areas used for DNA extraction in the endometrial (A, B) and ovarian (C, D) carcinoma and the lung me...
Clinicopathological data for MOTs. Table S2. Summary of whole exome sequencing statistics. Table S3....
Figure S1. Result of sanger sequencing. (A) Eleven mutations which were sanger sequenced. (B) - (H) ...
Sample information of 587 ovarian patients and normal tissue samples with Copy number variation and ...
Table S1. The primer of Sanger sequence for specific genes mutation in FDOV1. (DOCX 15 kb
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Clinical description of cancer patients. Table S2. Statistics of whole-genome sequencing results. Ta...
Table S1. 48 genes included in the TruSeq Amplicon Cancer Panel (TSACP, Illumina), which includes 21...
Figure S2. Distribution of genes with novel mutations based on individual patients. (A) Distribution...
Statistics of sequencing results. Sequence coverage by Comprehensive Cancer Panel (Thermo Scientific...
Pathogenic mutations in BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) genes (n = 96) detected in 398 p...
Table S1. Sequencing parameters for 3 samples with the highest and 3 samples with the lowest sequenc...